Evaluation of inflammatory and biochemical markers in COVID-19 patients treated with tocilizumab alone or with the combination of tocilizumab and convalescent plasma transfusion

Karaarslan, Numan; DOGAN, Mustafa; YILMAZ, İbrahim; özbek, hanefi; bilir, bulent

doi:10.5455/annalsmedres.2022.02.048

Evaluation of inflammatory and biochemical markers in COVID-19 patients treated with tocilizumab alone or with the combination of tocilizumab and convalescent plasma transfusion

İbrahim YILMAZ, (İstanbul Rumeli Üniversitesi, Sağlık Hizmetleri Meslek Yüksekokulu, Sağlık Hizmetleri ve Teknikleri Bölümü, İstanbul, Türkiye)

Bülent BİLİR, (Namık Kemal Üniversitesi, Tıp Fakültesi, İç Hastalıkları Anabilim Dalı, Tekirdağ, Türkiye)

Mustafa DOĞAN, (Namık Kemal Üniversitesi Tıp Fakültesi Enfeksiyon Hastalıkları Ana Bilim Dalı, Tekirdağ, Türkiye)

Numan KARAARSLAN, (Haliç Üniversitesi, Tıp Fakültesi, Beyin Cerrahisi Anabilim Dalı, İstanbul,Türkiye)

HANEFİ ÖZBEK (İzmir Bakırçay Üniversitesi Tıp Fakültesi Tıbbi Farmakoloji Anabilim Dalı, İzmir, Türkiye)

Annals of Medical Research

5 1

Yıl: 2022 Cilt: 29 Sayı: 7 Sayfa Aralığı: 770 - 776 Metin Dili: İngilizce DOI: 10.5455/annalsmedres.2022.02.048 İndeks Tarihi: 07-09-2022

Evaluation of inflammatory and biochemical markers in COVID-19 patients treated with tocilizumab alone or with the combination of tocilizumab and convalescent plasma transfusion

Öz:

Abstract Aim: Macrophage activation syndrome (MAS) develops due to increased expression of systemic pro-inflammatory cytokines in patients with the 2019 novel coronavirus disease (COVID-19). Immune modulators have been used in anti-cytokine therapy, with the hypothesis that they can ensure cytokine inhibition and treat cytokine storm. The present study aimed to evaluate inflammatory and prognostic biomarkers in severe COVID-19 cases treated with tocilizumab (TCZ) alone or with the combination of tocilizumab and convalescent plasma transfusion (CPT). Materials and Methods: In this retrospective study, data archives of patients with severe acute respiratory syndrome coronavirus 2 (SARS-Cov-2) and who were treated with TCZ alone or the combination of CPT and TCZ were evaluated in line with the literature. The obtained data were statistically evaluated and the alpha significance value was taken as <0.05. Results: Post-treatment C-reactive protein (CRP) (76.19% in TCZ-administered group; 89.32% in TCZ+CPT-administered group) (P<0.05), troponin I (TNI) (25.64% in TCZadministered group; 90.39% in TCZ+CPT-administered group) (P<0.05), and ferritin (FER) (63.63% in the TCZ-administered group; 9.09% in the TCZ+CPT-administered) (P<0.05) levels were decreased compared to pre-treatment stage. The mean length of hospital stay was longer in the patients treated with TCZ alone (21.55±8.89 days) than in the patients treated with the combination of TCZ and CPT (27.09±13.66 days) (P<0.05). Conclusion: There was no significant difference between the groups in terms of demographic characteristics. The combination of TCZ and CPT treatment did not decrease the mortality. A significant decrease in CRP and TNI levels was observed in the patients treated with TCZ alone and with the combination of TCZ and CPT. A decrease in FER levels showed the effectiveness of the treatments.

Anahtar Kelime:

Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık

1. Stradner MH, Dejaco C, Zwerina J, Fritsch-Stork RD. Rheumatic musculoskeletal diseases and COVID-19 a review of the first 6 months of the pandemic. Front Med (Lausanne). 2020; 7: 562142.
2. Alvi MM, Sivasankaran S, Singh M. Pharmacological and nonpharmacological efforts at prevention, mitigation, and treatment for COVID-19. J Drug Target. 2020; 28: 742-54.
3. Sinha N, Balayla G. Hydroxychloroquine and COVID-19. Postgrad Med J. 2020;96: 550-5.
4. Karaarslan N, Dogan M, Yilmaz I, et al. Evaluation of treatment of patients with SARS-CoV-2 in line with literature. Maltepe Med J. 2020;12:49–58.
5. Doyno C, Sobieraj DM, Baker WL. Toxicity of chloroquine and hydroxychloroquine following therapeutic use or overdose. Clin Toxicol (Phila). 2021; 59: 12-23.
6. Coomes EA, Haghbayan H. Interleukin-6 in COVID-19: a systematic review and meta-analysis. MedRxiv. 2020; 30: 1–9.
7. Balashov D, Trakhtman P, Livshits A, et al. SARS-CoV-2 convalescent plasma therapy in pediatric patient after hematopoietic stem cell transplantation. Transfus Apher Sci. 2021; 60: 102983.
8. Mehta Y, Dixit SB, Zirpe KG, Ansari AS. Cytokine storm in novel coronavirus disease (COVID-19): expert management considerations. Indian J Crit Care Med. 2020; 24: 429-34.
9. Sheppard M, Laskou F, Stapleton PP, et al. Tocilizumab (Actemra). Hum Vaccin Immunother. 2017; 13: 1972-88.
10. McGonagle D, Sharif K, O’Regan A, Bridgewood C. The Role of Cytokines including Interleukin-6 in COVID-19 induced pneumonia and macrophage activation syndrome-like disease. Autoimmun Rev. 2020; 19: 102537.
11. Luo P, Liu Y, Qiu L, et al. Tocilizumab treatment in COVID-19: a single center experience. J Med Virol. 2020; 92: 814-8.
12. Kumar N, Sharma N, Mehan S. Connection between JAK/STAT and PPARγ signaling during the progression of multiple sclerosis: Insights into the modulation of T-cells and immune responses in the brain. Curr Mol Pharmacol. 2021; 14: 823-37.
13. Mehta P, McAuley DF, Brown M, et al. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet. 2020; 395: 1033.
14. Scheller J, Rose-John S. Interleukin-6 and its receptor: from bench to bedside. Med Microbiol Immunol. 2006; 195: 173–83.
15. McGonagle D, Sharif K, O’Regan A, Bridgewood C. Interleukin6 use in COVID-19 pneumonia related macrophage activation syndrome. Autoimmun Rev. 2020; 19: 102537.
16. Wu J, Shen J, Han Y, et al. Upregulated IL-6 indicates a poor COVID-19 prognosis: call for tocilizumab and convalescent plasma treatment. Front Immunol. 2021; 12: 598799.
17. Dash P, Mohapatra S, Ghosh S, Nayak B. A scoping ınsight on potential prophylactics, vaccines and therapeutic weaponry for the ongoing novel coronavirus (COVID-19) pandemic- a comprehensive review. Front Pharmacol. 2021; 11: 590154.
18. Heustess AM, Allard MA, Thompson DK, Fasinu PS. Clinical management of COVID-19: a review of pharmacological treatment options. Pharmaceuticals (Basel). 2021; 14: 520.
19. Gumus H, Demir A, Yukkaldıran A. Is mean platelet volume a predictive marker for the diagnosis of COVID-19 in children? Int J Clin Pract. 2021; 75: e13892.
20. Zhong Q, Peng J. Mean platelet volume/platelet count ratio predicts severe pneumonia of COVID-19. J Clin Lab Anal. 2021; 35: e23607.
21. Simadibrata DM, Calvin J, Wijaya AD, Ibrahim NAA. Neutrophil-to-lymphocyte ratio on admission to predict the severity and mortality of COVID-19 patients: A meta-analysis. Am J Emerg Med. 2021; 42: 60-9.
22. Panova-Noeva M, Wagner B, Nagler M et al. Comprehensive platelet phenotyping supports the role of platelets in the pathogenesis of acute venous thromboembolism - results from clinical observation studies. EBioMedicine. 2020; 60: 102978.
23. Ghaffari S, Parvizian N, Pourafkari L, et al. Prognostic value of platelet indices in patients with acute pulmonary thromboembolism. J Cardiovasc Thorac Res. 2020; 12: 56-62.
24. Faul F, Erdfelder E, Lang AG, Buchner A. G*Power 3: a flexible statistical power analysis program for the social, behavioral, and biomedical sciences. Behav Res Methods. 2007; 39: 175-91.
25. Faul F, Erdfelder E, Buchner A, Lang AG. Statistical power analyses using G*Power 3.1: tests for correlation and regression analyses. Behav Res Methods. 2009; 41: 1149-60.
26. Uluyol S, Kilicaslan S. Diagnostic value of neutrophillymphocyte ratios and mean platelet volumes in the activation of recurrent aphthous stomatitis. Indian J Otolaryngol Head Neck Surg. 2019; 71: 120-3.
27. Xiong B, Liu T, Luo P, et al. Prominent hypercoagulability associated with ınflammatory state among cancer patients with SARS-CoV-2 Infection. Front Oncol. 2020; 10: 1345.
28. Florindo HF, Kleiner R, Vaskovich-Koubi D, et al. Immunemediated approaches against COVID-19. Nat Nanotechnol. 2020; 15: 630-45.
29. Al Harthi S, Osali MA, Kindi NA, et al. Characteristics of the first 102 severe COVID-19 cases treated with convalescent plasma or tocilizumab or both in Al-Nahdha Hospital, Oman. Health Serv Res Manag Epidemiol. 2021; 8: 2333392820986639.
30. Dassarma B, Tripathy S, Matsabisa M. Emergence of ancient convalescent plasma (CP) therapy: To manage COVID-19 pandemic. Transfus Clin Biol. 2021; 28: 123-7.
31. O’Donnell MR, Grinsztejn B, Cummings MJ, et al. A randomized double-blind controlled trial of convalescent plasma in adults with severe COVID-19. J Clin Invest. 2021; 131: e150646.
32. Simonovich VA, Burgos Pratx LD, Scibona P, et al. A randomized trial of convalescent plasma in COVID-19 severe pneumonia. N Engl J Med. 2021; 384: 619-29.
33. Joyner MJ, Bruno KA, Klassen SA, et al. Safety update: COVID-19 convalescent plasma in 20,000 hospitalized patients. Mayo Clin Proc. 2020; 95: 1888-97.
34. Wood EM, Estcourt LJ, McQuilten ZK. How should we use convalescent plasma therapies for the management of COVID-19? Blood. 2021; 137: 1573-81.
35. Duan K, Liu B, Li C, et al. Effectiveness of convalescent plasma therapy in severe COVID-19 patients. Proc Natl Acad Sci U S A. 2020; 117: 9490-6.
36. Antwi-Amoabeng D, Kanji Z, Ford B, et al. Clinical outcomes in COVID-19 patients treated with tocilizumab: An individual patient data systematic review. J Med Virol. 2020; 92: 2516-22.
37. Liu Y, Liu SX, Cai Y, et al. Effects of combined aerobic and resistance training on the glycolipid metabolism and inflammation levels in type 2 diabetes mellitus. J Phys Ther Sci. 2015; 27:2365–71.
38. Kevadiya BD, Machhi J, Herskovitz J, et al. Pharmacotherapeutics of SARS-CoV-2 infections. J Neuroimmune Pharmacol. 2021; 16: 12-37.
39. Mady A, Aletreby W, Abdulrahman B, et al. Tocilizumab in the treatment of rapidly evolving COVID-19 pneumonia and multifaceted critical illness: A retrospective case series. Ann Med Surg (Lond). 2020; 60: 417-24.
40. Salama C, Han J, Yau L, et al. Tocilizumab in patients hospitalized with COVID-19 pneumonia. N Engl J Med. 2021; 384: 20-30.
41. Salvarani C, Dolci G, Massari M, et al. Effect of tocilizumab vs standard care on clinical worsening in patients hospitalized with COVID-19 pneumonia: a randomized clinical trial. JAMA Intern Med. 2021; 181: 24-31.
42. Yakar HI, Pazarli AC, Inonu Koseoglu H, et al. The effect of tocilizumab on severe COVID-19 infection: Review of current evidence. Tuberk Toraks. 2021; 69: 74-83.

APA	YILMAZ İ, bilir b, DOGAN M, Karaarslan N, özbek h (2022). Evaluation of inflammatory and biochemical markers in COVID-19 patients treated with tocilizumab alone or with the combination of tocilizumab and convalescent plasma transfusion. , 770 - 776. 10.5455/annalsmedres.2022.02.048
Chicago	YILMAZ İbrahim,bilir bulent,DOGAN Mustafa,Karaarslan Numan,özbek hanefi Evaluation of inflammatory and biochemical markers in COVID-19 patients treated with tocilizumab alone or with the combination of tocilizumab and convalescent plasma transfusion. (2022): 770 - 776. 10.5455/annalsmedres.2022.02.048
MLA	YILMAZ İbrahim,bilir bulent,DOGAN Mustafa,Karaarslan Numan,özbek hanefi Evaluation of inflammatory and biochemical markers in COVID-19 patients treated with tocilizumab alone or with the combination of tocilizumab and convalescent plasma transfusion. , 2022, ss.770 - 776. 10.5455/annalsmedres.2022.02.048
AMA	YILMAZ İ,bilir b,DOGAN M,Karaarslan N,özbek h Evaluation of inflammatory and biochemical markers in COVID-19 patients treated with tocilizumab alone or with the combination of tocilizumab and convalescent plasma transfusion. . 2022; 770 - 776. 10.5455/annalsmedres.2022.02.048
Vancouver	YILMAZ İ,bilir b,DOGAN M,Karaarslan N,özbek h Evaluation of inflammatory and biochemical markers in COVID-19 patients treated with tocilizumab alone or with the combination of tocilizumab and convalescent plasma transfusion. . 2022; 770 - 776. 10.5455/annalsmedres.2022.02.048
IEEE	YILMAZ İ,bilir b,DOGAN M,Karaarslan N,özbek h "Evaluation of inflammatory and biochemical markers in COVID-19 patients treated with tocilizumab alone or with the combination of tocilizumab and convalescent plasma transfusion." , ss.770 - 776, 2022. 10.5455/annalsmedres.2022.02.048
ISNAD	YILMAZ, İbrahim vd. "Evaluation of inflammatory and biochemical markers in COVID-19 patients treated with tocilizumab alone or with the combination of tocilizumab and convalescent plasma transfusion". (2022), 770-776. https://doi.org/10.5455/annalsmedres.2022.02.048

APA	YILMAZ İ, bilir b, DOGAN M, Karaarslan N, özbek h (2022). Evaluation of inflammatory and biochemical markers in COVID-19 patients treated with tocilizumab alone or with the combination of tocilizumab and convalescent plasma transfusion. Annals of Medical Research, 29(7), 770 - 776. 10.5455/annalsmedres.2022.02.048
Chicago	YILMAZ İbrahim,bilir bulent,DOGAN Mustafa,Karaarslan Numan,özbek hanefi Evaluation of inflammatory and biochemical markers in COVID-19 patients treated with tocilizumab alone or with the combination of tocilizumab and convalescent plasma transfusion. Annals of Medical Research 29, no.7 (2022): 770 - 776. 10.5455/annalsmedres.2022.02.048
MLA	YILMAZ İbrahim,bilir bulent,DOGAN Mustafa,Karaarslan Numan,özbek hanefi Evaluation of inflammatory and biochemical markers in COVID-19 patients treated with tocilizumab alone or with the combination of tocilizumab and convalescent plasma transfusion. Annals of Medical Research, vol.29, no.7, 2022, ss.770 - 776. 10.5455/annalsmedres.2022.02.048
AMA	YILMAZ İ,bilir b,DOGAN M,Karaarslan N,özbek h Evaluation of inflammatory and biochemical markers in COVID-19 patients treated with tocilizumab alone or with the combination of tocilizumab and convalescent plasma transfusion. Annals of Medical Research. 2022; 29(7): 770 - 776. 10.5455/annalsmedres.2022.02.048
Vancouver	YILMAZ İ,bilir b,DOGAN M,Karaarslan N,özbek h Evaluation of inflammatory and biochemical markers in COVID-19 patients treated with tocilizumab alone or with the combination of tocilizumab and convalescent plasma transfusion. Annals of Medical Research. 2022; 29(7): 770 - 776. 10.5455/annalsmedres.2022.02.048
IEEE	YILMAZ İ,bilir b,DOGAN M,Karaarslan N,özbek h "Evaluation of inflammatory and biochemical markers in COVID-19 patients treated with tocilizumab alone or with the combination of tocilizumab and convalescent plasma transfusion." Annals of Medical Research, 29, ss.770 - 776, 2022. 10.5455/annalsmedres.2022.02.048
ISNAD	YILMAZ, İbrahim vd. "Evaluation of inflammatory and biochemical markers in COVID-19 patients treated with tocilizumab alone or with the combination of tocilizumab and convalescent plasma transfusion". Annals of Medical Research 29/7 (2022), 770-776. https://doi.org/10.5455/annalsmedres.2022.02.048